Hepatocellular Carcinoma, Liver Transplant
Conditions
Keywords
Hepatocellular carcinoma, Liver transplantation, PET CT, Fluorodeoxyglucose, Fluorodeoxyglucose, Choline
Brief summary
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.
Interventions
RADIATIONPET TDM FDG-Choline
Performing an FDG TDM PET and a Choline TDM PET at two different times
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient candidate for liver transplantation for hepatocellular carcinoma from the University Hospital of Lille and Rouen, whose therapeutic transplantation project has been validated and having an AFP score ≤ 2 (diagnosis of HCC defined on non-invasive imaging criteria according to the recommendations of EASL-EORTC 2012 or confirmed histologically). * No opposition to participating in the study. * Patient affiliated to a social security scheme
Exclusion criteria
* Patient with an AFP score ≥ 3 * Patient contraindicated to PET FDG or Choline. * Other tumor: Cholangiocarcinoma. * Diabetes unbalanced HbA1c\> 9%, and fasting hyperglycemia (\> 2g / L) which does not allow the completion of the PET examination. * Patient under guardianship or curatorship. * Pregnant or breastfeeding woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline | through study completion an average of 1 year | Composite endpoint corresponding to the rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline with a negative standard assessment (thoracic CT, abdominal imaging by CT or MRI) or patient not included on the list due to locally advanced disease not compatible with the graft (AFP score ≥ 3 or infiltrating HCC) not identified by the standard assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characteristics of PET FDG-Choline PET binding (defined as below) and the degree of tumor differentiation of HCC on the hepatectomy specimen (well differentiated/ moderate differentiation/ undifferentiated): | At time of liver transplantation (comparison of TEP baseline and HCC obtained on the hepatectomy analysis) | Presence/absence of a double fixation TEP FDG and TEP Choline B. Presence of a single TEP FDG or Choline binding C. No FDG-Choline binding. |
| Binding intensity (SUV) of PET TDM FDG-Choline and the degree of tumor differentiation of HCC on the hepatectomy specimen (well differentiated/ moderate differentiation/ undifferentiated) | At time of liver transplantation (comparison of TEP baseline and HCC obtained on the hepatectomy analysis | — |
| Binding intensity (SUV) of PET TDM FDG-Choline and risk of waiting list dropout for progression of HCC outside transplant criteria based on aFP score | Analysis on the access to liver transplantation after 24 month. | — |
| Binding intensity (SUV) of PET TDM FDG-Choline and risk of HCC recurrence in the 5 years after LT | 5 years after transplantation. Screening for HCC recurrence with CT and abdominal scan every 6 month during 5 years. | — |
| Binding intensity (SUV) of PET TDM FDG-Choline and the last aFP value before transplantation or WL dropout. | Last aFP value before LT or WL dropout. Maximal estimated time before transplant: 2 years | — |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORGuillaume Lassailly, MD
University Hospital, Lille
Outcome results
None listed